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Conclusions. Hyperglycemia was associated with glomeru-The cyclin kinase inhibitor p21WAF1/CIP1 is required for glomeru-
lar hypertrophy in p21 1/1 mice. Despite the increase inlar hypertrophy in experimental diabetic nephropathy.
TGF-b1 mRNA, diabetic p21 2/2 mice did not develop glomer-Background. Diabetic nephropathy is characterized by glo-
ular hypertrophy, providing evidence that the cyclin kinasemerular hypertrophy. We have recently shown that experimen-
inhibitor p21 may be required for diabetic glomerular hypertro-tal diabetes mellitus is associated with an increase in glomerular
expression of the cyclin kinase inhibitor p21WAF1/CIP1 (p21). Fur- phy induced by TGF-b1. The loss of p21 increases tubular but
thermore, in vitro glucose-induced mesangial cell hypertrophy not glomerular cell proliferation in diabetic nephropathy. The
is also associated with an up-regulated expression of p21. In absence of glomerular hypertrophy appears protective of renal
this study, we tested the hypothesis that p21 mediates diabetic function in diabetic mice.
glomerular hypertrophy in vivo.
Methods. Experimental diabetes mellitus was induced by
streptozotocin in mice in which p21 was genetically deleted
Diabetic nephropathy is the leading cause of end-stage(p21 2/2) and in wild-type mice (p21 1/1). Kidney biopsies
were obtained from diabetic and control (citrate injected) renal disease (ESRD) in the United States [1]. Unlike
p21 1/1 and p21 2/2 mice at day 60. The tissue was used for most forms of ESRD, the kidney size is typically in-
morphologic studies of glomerular size (measured by computer creased in diabetes, at least early in the natural history
image-analysis system), glomerular cellularity (cell count), glo-
of the disease [2–6]. This is primarily because of twomerular matrix expansion (silver stain), apoptosis (TUNEL),
underlying events. First, although diabetic nephropathyand expression of transforming growth factor-b1 (TGF-b1) by
in situ hybridization. may be associated with some low-grade glomerular cell
Results. The glomerular tuft area increased 11.21% in dia- proliferation [7], hypertrophy is the major means of en-
betic p21 1/1 mice at day 60 compared with control (3329.98 6
largement in the glomerulus [reviewed in 8, 9]. Second,244.05 mm2 vs. 2994.39 6 176.22 mm2, P 5 0.03), and the glomer-
diabetes is associated with increased tubular prolifera-ular cell count did not change in diabetic p21 1/1 mice at day
60 compared with the control. These findings are consistent tion and hypertrophy [reviewed in 10]. Normalizing
with glomerular hypertrophy. In contrast, the glomerular tuft blood glucose levels prevent these growth events and
area did not increase in diabetic p21 2/2 mice at day 60 the development of progressive glomerular sclerosis and,compared with the control (3544.15 6 826.49 vs. 3449.15 6
in some cases, may even reverse glomerular sclerosis109.65, P 5 0.82), nor was there an increase in glomerular cell
over time [11].count (41.41 6 13.18 vs. 46.95 6 3.00, P 5 0.43). Diabetic
p21 1/1 mice, but not p21 2/2 mice, developed an increase The mechanisms underlying the development of dia-
in proteinuria at day 60 compared with the control. Tubular cell betic glomerular hypertrophy have not been fully estab-
proliferation, measured by proliferating cell nuclear antigen
lished, and it is also not known why the glomerulusimmunostaining, was increased in both diabetic p21 1/1
undergoes little or no proliferation in diabetes, whereas(2.1-fold) and p21 2/2 (7.61-fold) mice compared with con-
trols. Glomerular cell apoptosis did not increase in diabetic tubular epithelial cell proliferation is readily demon-
mice. Although glomerular TGF-b1 mRNA levels increased in strated. There is evidence to support a role for growth
both strains of diabetic mice at day 60, the glomerular matrix factors such as TGF-b [12–16], certain intracellular sig-did not expand.
naling pathways [17], and specific transcription factors
[18–20] in mediating diabetic-associated glomerular hy-
Key words: glomerulus, cyclin, hypertrophy, proliferation, diabetes, p21. pertrophy. However, attempts only recently have been
made to determine the role of cell cycle regulatory pro-
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cyclin during each phase of the cell cycle [21, 22]. Cyclin and tissues were fixed in methyl Carnoy’s solution or
10% buffered formalin as previously described [30].kinase inhibitors (CKIs) bind to cyclin-CDK complexes,
which inactivate the kinase, causing cell cycle arrest and
Urinary proteinthe inhibition of proliferation [23]. There are two families
of CKIs, which are classified according to their structural To evaluate proteinuria, mice were placed in meta-
bolic cages with free access to water but not chow, andhomology and which cyclin-CDK complexes they inhibit.
The INK4 family (p15, p16, p18, and p19) inhibits CDKs a 24-hour urine collection was obtained one day before
sacrifice. Urinary protein was measured using the sulfa-active in the G1 phase of the cell cycle [24, 25], whereas
members of the Cip/Kip family, currently comprising salicylic acid (SSA) method [31]. Briefly, urine was di-
luted in phosphate-buffered saline, and three parts ofp21CIP1/WAF1 (p21), p27KIP1, and p57KIP2, contain a CDK-
binding domain and inhibit both G1- and S-phase CDKs SSA was added to one part of diluted urine. Precipitated
protein was measured by spectrophotometry at an opti-[26–29].
When a cell engages the cell cycle, the protein content cal density of 650 nm. The protein concentration was
measured against a standard curve, and the 24-hour ex-increases in anticipation of preparing the cell for division
[21]. However, DNA synthesis occurs only during the S cretion was determined by measuring urine volume and
was reported as milligrams per 24 hours.phase of the cell cycle. Hypertrophy is defined as an
increase in the ratio of protein to DNA [10]. We and
Morphometric measurementsothers have hypothesized that one mechanism of hyper-
trophy is the inhibition of DNA synthesis in cells that To determine the role of p21 in diabetic glomerular
hypertrophy, the glomerular tuft area, a measure of glo-have engaged the cell cycle. Accordingly, we have been
interested in the potential role of specific CKIs in the merular size, was assessed [32, 33] on periodic acid-Schiff
(PAS)–stained slides. In this study, we used an Optimaspathogenesis of diabetic glomerular hypertrophy. We
have recently shown that glucose-induced mesangial cell computer image analysis system, version 6.1 (Bothell,
WA, USA). A Leica DMRB microscope was used andhypertrophy in vitro is associated with increased levels
of the CKI p21 [30]. Furthermore, glomerular hypertro- was connected to a computer system via a Nikon UFX
camera lens and a microimage video system. Images werephy in the streptozotocin (STZ) model of diabetic ne-
phropathy in mice is also associated with increased p21 viewed using a Sony computer monitor. To measure the
glomerular tuft area, a line was manually drawn aroundexpression [30].
In this study, we have extended these studies by induc- the boundary of each glomerular tuft in a blinded manner
by one of the authors. The area inside the line (glomeru-ing experimental diabetes in p21 1/1 and p21 2/2 mice
to test whether the presence of p21 is essential for the lar tuft area) was measured in mm2. Measurements were
done on 20 consecutive cortical glomeruli at a 3630observed hypertrophy in these experimental systems.
magnification. Pilot studies showed that evaluating 20
glomeruli in each kidney biopsy was sufficient to obtain
METHODS
statistically significant morphometric measurements that
Animal model and experimental design were not meaningfully altered by evaluating up to 90
additional glomeruli per biopsy (data not shown). Glo-Experimental diabetes mellitus was induced in p21
wild-type (1/1) mice (N 5 7) and in p21 null (2/2) meruli were excluded if the tuft area was more than two
sd from the mean (,1% excluded). The tuft area wasmice (N 5 12) with single intraperitoneal injections of
streptozotocin (STZ; 160 mg/kg; Sigma, St. Louis, MO, expressed as mean 6 sd for both mouse strains at each
time point. Immunostaining for p21 was performed asUSA) on two consecutive days [13, 30]. Mice were six
to eight weeks old. A second group of age-matched previously reported using a rabbit polyclonal antibody
(Santa Cruz Biotechnology, Santa Cruz, CA, USA).p21 1/1 (N 5 5) and p21 2/2 (N 5 4) mice were
injected with sodium citrate (vehicle for STZ) and served
Glomerular cell countas controls. A third group of normal age-matched un-
manipulated p21 1/1 (N 5 11) and p21 2/2 (N 5 7) In order to determine if glomerular cell proliferation
was increased in the absence of p21 in experimentalmice served as baseline.
Blood glucose was measured in p21 1/1 and p21 2/2 diabetic nephropathy, the glomerular cell number was
measured on PAS-stained slides. The total number ofmice prior to intraperitoneal injections of STZ and ci-
trate, three days postinjection and at sacrifice using the cells in each glomerular tuft was measured using the
Optimas computer image analysis system, and the glo-One Touch glucometer (Lifescan INC, Milpitas, CA,
USA). Prior to sacrifice, body weight was measured in merular cell count was expressed as mean 6 sd for indi-
vidual animals. Twenty consecutive cortical glomeruligrams. Control and diabetic p21 1/1 and p21 2/2 mice
were sacrificed at day 60, when the kidney weight was were evaluated in each control and diabetic p21 1/1
and p21 2/2 animal.also measured in grams. Kidney biopsies were obtained,
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Measuring DNA synthesis counterstained with hematoxylin and eosin. Sense con-
trols were run with every section, and mouse skin con-DNA synthesis was evaluated by proliferating cell nu-
taining granulation and scar tissue was used as a concur-clear antigen (PCNA) staining in methyl Carnoy’s fixed
rent positive hybridization control.tissue. A mouse monoclonal IgM antibody (Coulter
clone #6604541; Coulter, Miami, FL, USA) was used as Measuring glomerular matrix expansion
a primary antibody at a concentration of 1:700, followed
To measure glomerular matrix expansion, the modi-by a horseradish peroxidase rat antimouse IgM (Zymed,
fied Gomori’s methenamine silver stain was used, andSan Francisco, CA, USA), as described elsewhere [30].
immunostaining was performed for collagen type IV us-Renal tissue from a mouse uninephrectomy model was
ing a goat antitype IV collagen antibody (#1340-01;used as positive control tissue for PCNA staining.
Southern Biotech, Birmingham, AL, USA), laminin us-To identify renal tubular cells better, an eosin counter-
ing a rabbit antirat IgG antibody (Chemicon, Temecula,stain was added, and PCNA-positive cells were counted
CA, USA), and fibronectin using a rabbit antirat anti-in the renal cortical tubules. PCNA-positive cells were
body (Chemicon). Glomerular tuft immunostaining wascounted in all cortical fields (at 3400 magnification) that
quantitated for each matrix protein and silver stain usingshowed the renal capsule. Overlapping of the fields was
the Optimas computer image analysis system. The coloravoided, and the average number of cells that stained
threshold was set by marking three to five separate pixelspositive for PCNA in the tubules per high power field
in areas of positive staining in 20 consecutive glomerular(HPF) was calculated.
tufts in each animal. Positive staining was expressed as
a percentage of the glomerular tuft area.Terminal deoxynucleotidyl transferase-mediated nick
end labeling staining
Statistical analysis
To determine if glomerular apoptosis (programmed
Statistical analysis was performed by the unpairedcell death) was increased in diabetic animals, apoptosis
t-test using the StatView computer statistics programwas measured by terminal deoxynucleotidyl transferase-
(version 4.5; Abacus Concepts, Berkeley, CA, USA).
mediated nick end labeling (TUNEL) staining on forma-
Statistical significance was defined as P , 0.05. All values
lin-fixed tissues, as described elsewhere [34, 35].
were expressed as mean 6 sd.
Transforming growth factor-b1 in situ hybridization
RESULTSBecause transforming growth factor-b1 (TGF-b1) has
previously been shown to mediate diabetic glomerular Glucose increased in both mouse strains
hypertrophy [13], TGF-b1 mRNA was evaluated by in Blood glucose levels increased significantly in STZ-
situ hybridization. A previously characterized mouse injected p21 1/1 mice compared with their controls (ci-
TGF-b1 cDNA clone was used (gift of Dr. H.L. Moses, trate-injected p21 1/1 mice) at day 60 (506.29 6 60.54
Vanderbilt University, Nashville, TN, USA) [36, 37]. mg/dl vs. 184.6 6 28.5 mg/dl, P , 0.0001; Table 1). Simi-
The cDNA was trancribed into 35S-labeled antisense and larly, blood glucose levels increased in STZ-injected
sense cRNA probes corresponding to 974 bp (421 to p21 2/2 mice compared with control (citrate-injected
1395 bp) of mouse TGF-b1. In situ hybridization followed p21 2/2 mice) at day 60 (439.42 6 64.79 mg dl vs.
a method previously described [38]. Briefly, formalin- 133.75 6 9.46 mg/dl, P , 0.0001; Table 1).
fixed, 4 mm tissue sections were digested with 10 mg/ml
Proteinuria did not increase in diabetic p21 2/2 miceproteinase K and prehybridized for two hours in 100 ml
of prehybridization buffer [0.3 m NaCl, 20 mm Tris, pH To evaluate the effect of diabetes on protein excretion,
8.0, 5 mm ethylenediaminetetraacetic acid (EDTA) 3 1 24-hour urinary protein was measured and is shown in
Denhardt’s solution, 10% dextran sulfate, and 10 mm Table 1. Urinary protein was 5.77-fold higher in diabetic
dithiothreitol (DTT)]. Hybridization was commenced by p21 1/1 mice compared with control (70.72 6 13.74 vs.
adding 5 3 105 cpm of 35S-labeled riboprobe in 50 ml of 12.26 6 3.71 mg/24 hr, P , 0.0001). In contrast, urinary
prehybridization buffer. Overnight incubation at 508C protein did not increase significantly in diabetic p21 2/2
was followed by 32 standard saline citrate (SSC) washes mice compared with controls (23.53 6 8.66 vs. 30.08 6
and was then RNase A digested (20 mg/ml) for 30 min- 17.33 mg/24 hr, P 5 0.65).
utes at 378C. Three stringency washes comprising 30.1
Normal glomerular histology in diabetic micestandard saline citrate, 0.5% Tween at 508C were fol-
at day 60lowed by dehydration and air drying. The slides were
dipped in photographic emulsion (Kodak NTB2), ex- The renal pathology in control and diabetic p21 1/1
posed at 48C for three weeks, developed with D-19 devel- and p21 2/2 mice was evaluated by four of the authors
(M.A, P.A.J.B., C.E.A, S.J.S.) on PAS- and silver-stainedoper (Eastman Kodak Co., Rochester, NY, USA), and
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Table 1. Animal data in control and diabetic p21 1/1 and p21 2/2 mice at day 60
Kidney weight Body weight
Blood glucose Urine protein Kidney to body
Animal group mg/dl mg/24 hr g weight ratio
p21 1/1 Control 184628.5 12.2663.71 0.369 60.03 27.060.93 0.01460.001
(N55)
p21 1/1 Diabetic 506.3660.5a 70.72613.74a 0.39660.04 23.0762.73 0.017 60.001
(N57)
p21 2/2 Control 133.769.5 30.08 617.33 0.42 60.08 29.3761.7 0.014 60.002
(N54)
p21 2/2 Diabetic 439.4664.8b 23.5368.66 0.406 60.09 22.8763.75 0.018 60.003
(N512)
aP , 0.001 vs. p21 1/1 Control
bP , 0.001 vs. p21 2/2 Control
Fig. 1. PAS staining at day 60. The glomerular histology was normal in control (citrate injected) p21 1/1 (A) and p21 2/2 (C) mice at day 60.
The glomerular tuft area, but not glomerular cellularity, increased in diabetic p21 1/1 mice (B). The glomerular tuft area did not change in
diabetic p21 2/2 mice (D).
sections (Fig. 1). There was no obvious increase in the Glomerular hypertrophy was absent in diabetic
p21 2/2 micemesangial expansion in diabetic mice nor was there any
thickening of the glomerular basement membranes. In The kidney to body weight ratios were calculated in
less than 5% of glomeruli, mild mesangiolysis and mi- individual mice, and the results are shown in Table 1.
croaneurysms were noted, but there was no quantitative Although there was a trend toward an increase in kidney
difference between p21 2/2 and p21 1/1 mice. No to body weight ratio in diabetic mice, the increase did
abnormalities were noted in the renal blood vessels in not reach statistical significance at the time point studied.
diabetic animals, and the tubular epithelial cells were Hence, the glomerular tuft area was used as a measure
of glomerular hypertrophy [32]. In age-matched unmani-grossly normal.
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Table 2. Glomerular tuft area (mean 6 sd), a measure of glomerular in diabetic p21 2/2 mice compared with controls at day
hypertrophy, increased in diabetic p21 1/1 mice, but not in
60 (results not shown). There was also no increase indiabetic p21 2/2 mice, compared with controls
glomerular immunostaining for collagen type IV, lami-
Control Diabetic nin, and fibronectin in diabetic p21 2/2 and p21 1/1
day 60 P value mice at day 60 compared with controls (results not
p21 1/1 2994.396176.22 3329.986244.05 0.03 shown).
p21 2/2 3449.156109.65 3544.156826.49 0.82
Glomerular TGF-b1 is increased in diabetic mice
Transforming growth factor-b1 mRNA was assessed
by in situ hybridization. All slides were labeled during
Table 3. Glomerular cell number did not increase in diabetic
the same run to minimize technical differences that couldp21 1/1 and p21 2/2 mice at day 60 compared with controls
occur between procedures. Control p21 1/1 mice re-
Control Diabetic vealed occasional positive glomerular and interstitial
day 60 P value cells using the antisense probe. TGF-b1 mRNA was in-
p21 1/1 38.8361.91 36.2664.22 0.24 creased in glomerular and interstitial cells in diabetic
p21 2/2 46.9563.00 41.41613.18 0.43 p21 1/1 mice (Fig. 2). However, an induction of diabetes
resulted in a marked glomerular (and interstitial) hybrid-
ization signal in p21 2/2 mice, both compared with con-
trol p21 2/2 and diabetic p21 1/1 mice (Fig. 2). Because
pulated mice, there was an increase in glomerular tuft of the scattering effect of silver grains in this technique,
area in p21 2/2 mice compared with p21 1/1 mice the exact localization to particular glomerular cell types
(2973.31 6 160.64 vs. 2567.48 6 265.36, P 5 0.04). There was not possible. Sense control slides revealed only slight
was an 11.21% increase in glomerular tuft area in dia- background levels of silver grain staining.
betic p21 1/1 mice at day 60 compared with control
(citrate injected; Table 2). In contrast, the glomerular Tubular DNA synthesis is increased in diabetic
tuft area did not increase in diabetic p21 2/2 mice at p21 2/2 mice
day 60 compared with the control (Table 2). Because previous studies have shown that diabetes is
To determine whether the increase in glomerular tuft associated with tubular cell proliferation [4, 5], we were
area in diabetic p21 1/1 mice was due to cell hypertro- particularly interested in determining if DNA synthesis
phy or increased cell number and whether glomerular was different in this renal compartment in diabetic
cellularity was increased in diabetic p21-deficient ani- p21 1/1 and p21 2/2 mice. There was a 2.1-fold increase
mals, glomerular tuft cell count was measured at day 60. in PCNA staining in tubular cells in diabetic p21 1/1
There was no difference in glomerular tuft cell count in mice at day 60 compared with control (3.08 6 0.46 vs.
diabetic p21 1/1 mice at day 60 compared with control 1.47 6 0.46 cells per HPF, P 5 0.0001). Moreover, there
p21 1/1 mice (Table 3). Similarly, there was no differ- was a 7.61-fold increase in PCNA staining in tubular cell
ence in glomerular tuft cell count in diabetic p21 2/2 in diabetic p21 2/2 mice at day 60 compared with control
mice at day 60 compared with control p21 2/2 mice (6.66 6 3.16 vs. 0.87 6 0.12 cells per HPF, P 5 0.003).
(Table 3). These results and the absence of an increase TUNEL staining, a measure of apoptosis, was not de-
in extracellular matrix proteins (discussed later in this tected in the glomeruli of control or diabetic p21 1/1
article) show that the early increase in glomerular tuft and p21 2/2 mice at day 60.
area in diabetic p21 1/1 mice was consistent with glo-
merular cell hypertrophy. In contrast, glomerular hyper-
DISCUSSIONtrophy was not detected in diabetic p21 2/2 mice despite
The principle finding in this study is the demonstrationa similar degree of hyperglycemia.
that the absence of the CKI p21 prevents the occurrenceThere was no difference in glomerular immunostain-
of glomerular hypertrophy in diabetic mice and that thising for p21 in diabetic and control p21 1/1 mice at day
occurs despite an increase in TGF-b1 as measured by60 (results not shown).
synthesis of new mRNA. We demonstrated that glomer-
Glomerular matrix is not increased in diabetic ular hypertrophy in diabetic p21 1/1 mice was associ-
p21 2/2 mice ated with proteinuria, but proteinuria was not increased
in the absence of glomerular hypertrophy in diabeticGlomerular matrix expansion was quantitated in con-
trol and diabetic animals at day 60. There was no increase p21 2/2 mice. These results indicate a possible func-
tional defect that can be linked to what is usually identi-in silver staining and PAS staining in diabetic p21 1/1
mice compared with controls (results not shown). Simi- fied as the earliest structural alteration in human diabetic
nephropathy [3].larly, silver staining and PAS staining was not increased
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Fig. 2. Transforming growth factor-b1 (TGF-b1) in situ hybridization at day 60. There was an increase in TGF-b1 mRNA in glomeruli of diabetic
p21 1/1 (B) and p21 2/2 (D) mice compared with their respective controls (A and C).
The hallmark of experimental and human diabetic ne- phy, was not increased in diabetic p21 2/2 mice com-
pared with control (citrate injected) p212/2 mice.phropathy is an increase in glomerular size [reviewed in
3, 8, 9, 39]. Early in the course of disease, the increase In this study, we used the glomerular tuft area as a
measure of glomerular hypertrophy. Although the pro-in glomerular size is predominantly caused by cellular
hypertrophy. Later in the course of disease, increased tein to DNA ratio may be more specific, we did not
perform these measures in this study because of theglomerular size is due to hypertrophy and the accumula-
tion of extracellular matrix proteins. Hypertrophy is de- difficulty in obtaining a tubule-free glomerular prepara-
tion by isolation in mice. Second, the kidney to bodyfined as an increase in the cellular protein to DNA ratio
[10], which has led our group and others to ask if hyper- weight ratio has been used as a gauge of kidney growth
in diabetes. However, because 70% of the kidney weighttrophy is due to an increase in cyclin-kinase inhibitors,
which are proteins that inhibit DNA synthesis. is the tubular fraction (which proliferates in diabetes),
this is not a sensitive measure of glomerular size. Further-We have recently shown that hyperglycemia-induced
mesangial cell hypertrophy in vitro was associated with more, the body weight decreases in diabetes, which in-
creases the ratio. Finally, as discussed later here, theincreased levels of the CKI p21. Moreover, glomerular
hypertrophy in experimental diabetic nephropathy in increase in glomerular tuft area in this study occurred
in the absence of an increase in cellularity or extracellularvivo was associated with a substantial increase in glomer-
ular immunostaining for p21 [30]. Thus, in this study, matrix proteins, results that are consistent with hypertro-
phy as a cause of increased glomerular tuft area.we asked whether p21 was required for hyperglycemia-
induced glomerular hypertrophy. Indeed, hyperglycemia A role for CKIs in mediating diabetic and nondiabetic
renal hypertrophy is emerging. Wolf et al showed thatwas associated with glomerular hypertrophy in p21 1/1
mice compared with control p21 1/1 mice. However, hyperglycemia increased levels for the CKI p27Kip1 (p27)
in mesangial cells in vitro [40]. Furthermore, reducingthe first major finding in this study was that despite a
marked increase in hyperglycemia induced by STZ, the p27 levels with antisense prevented glucose-induced
mesangial cell hypertrophy in vitro [40]. Wolf et al alsoglomerular tuft area, a measure of glomerular hypertro-
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showed increased expression for p27 in both the STZ cle) may limit glomerular cell proliferation through a
p21-independent mechanism.and genetically determined (db/db) models of diabetic
The cytokine TGF-b has been of major interest innephropathy [41]. A role for CKIs has also been shown
renal and nonrenal disease because it increases the pro-in renal tubular cell hypertrophy. It has been shown
duction of extracellular matrix proteins and also has po-that p21, but not the CKI p15, mediates angiotensin II-
tent effects on cell growth, where it is antiproliferativeinduced proximal tubular cell hypertrophy in vitro, and
to glomerular cells in vitro [45], converts tubular epithe-Wolf and Stahl demonstrated a role for p27 in angioten-
lial cell proliferation to hypertrophy [46], and inducessin II-induced hypertrophy in vitro [42]. In this study,
mesangial cell hypertrophy [47]. TGF-b expression in-using mice genetically deficient for p21, our results show
creases in mesangial cells exposed to high glucose inthat the CKI p21 may be required for glomerular hyper-
vitro [48], and the glomerular expression for TGF-b1trophy in vivo. Although the kidneys from unmanipu-
increases during glomerular hypertrophy in experimen-lated p21 2/2 mice are histologically normal by light
tal and human diabetic nephropathy [12, 14, 16, 49].and electron microscope, and the renal function is nor-
Furthermore, neutralizing TGF-b prevents diabetic glo-mal, the glomerular tuft area was larger than in unmani-
merular hypertrophy [13]. Taken together, these studiespulated p21 1/1 mice. The reason for this is not clear.
show a role for TGF-b in hypertrophy of diabetic ne-Many forms of immune- and nonimmune-mediated
phropathy.glomerular injury are associated with glomerular cell
A link between TGF-b and the cell cycle has beenproliferation. In contrast, glomerular cell proliferation
shown. TGF-b1 increases the levels for p21 in certainis not marked in experimental and human diabetic ne-
nonrenal cells in vitro that may be responsible in part forphropathy [7]. Moreover, recent studies have shown that
the antiproliferative effects of TGF-b [50–52]. However,glomerular cell counts decrease in diabetic nephropathy
little is known about the role of p21 in mediating hyper-[43]. CKIs prevent and inhibit renal and nonrenal cell
trophy induced by TGF-b, and we were therefore inter-proliferation in vitro [23]. Accordingly, we hypothesized
ested in studying the relationship of TGF-b1 and glomer-a priori that the absence of p21 (in p21 2/2 mice) would
ular hypertrophy in diabetic p21 2/2 mice. In this study,be associated with increased glomerular cell proliferation
we showed a marked increase in glomerular TGF-b1following the onset of hyperglycemia. However, a second
mRNA in diabetic p21 1/1 and p21 2/2 mice. However,finding in this study was that the glomerular cell count
a third major finding in this study was that despite thedid not increase in diabetic p21 2/2 mice and diabetic
increase in TGF-b1 mRNA synthesis by intrinsic cellsp21 1/1 mice. In contrast, tubular epithelial cell DNA
comprising the renal parenchyma, glomerular hypertro-synthesis increased in diabetic p21 1/1 and p21 2/2
phy was not detected in diabetic p21 2/2 mice at day
mice, results that have been previously shown in diabetic
60. Taken together, these results show that p21 is re-
animals. Moreover, tubular epithelial cell DNA synthesis quired for TGF-b1–induced diabetic glomerular hyper-was more pronounced in diabetic p21 2/2 mice com- trophy in vivo.
pared with diabetic p21 1/1 mice. These results suggest Although hypertrophy is the predominant glomerular
a differential effect of p21 on tubular epithelial cells and lesion in the earlier phase of diabetic nephropathy, the
glomerular cells during hyperglycemia. later stages are characterized by increased extracellular
There are a number of potential explanations about matrix protein accumulation, leading to glomeruloscle-
why glomerular hypercellularity did not increase in dia- rosis. In this study, glomerular matrix accumulation did
betic p21 2/2 mice. First, the cell number may have not increase in both strains of diabetic mice at day 60,
decreased by apoptosis [43]. Indeed, Megyesi, Safirstein, despite the increase in TGF-b1. However, the lack of
and Price showed that tubular cell apoptosis increased in increased matrix proteins in diabetic mice at the early
p21 2/2 mice with cisplatinum-induced renal cell injury time points studied here is consistent with the findings
[44]. In contrast, in this study, glomerular TUNEL stain- of others, who show that matrix proteins accumulate
ing did not increase in diabetic p21 1/1 mice and late in the course of human and experimental diabetes,
p21 2/2 mice. However, apoptosis may have occurred including the STZ mouse model (Fuad Ziyadeh, personal
at different time points not studied here. Furthermore, communication). Striker et al showed that collagen IV
if apoptosis increased in podocytes, cell loss into the and laminin expression were increased in STZ-induced
urinary space may make it difficult to detect. Second, the diabetes in mice after 12 weeks of hyperglycemia, which
lack of (expected) glomerular hypercellularity in diabetic was significantly later in the course of hyperglycemia
p21 2/2 mice may be that hyperglycemia is not sufficient compared with this study. Moreover, the increase in ma-
to increase the expression and activity of cyclins and trix proteins was mouse-strain specific [53, 54]. Thus,
cyclin-dependent kinases required for DNA synthesis further long-term studies are needed to determine the
[30]. Third, the increase in expression for the antiprolif- role of p21 on the accumulation of glomerular extracellu-
lar matrix proteins. However, the absence of a detectableerative growth factor TGF-b (discussed later in this arti-
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APPENDIX
Abbreviations used in this article are: CDK, cyclin dependent ki-
nase; CKI, cyclin kinase inhibitor; DTT, dithiothreitol; EDTA, ethyl-
enediaminetetraacetic acid; ESRD, end-stage renal disease; p21,
p21CIP1, WAF1; p21 1/1, p21 wild-type mouse; p21 2/2, p21 null mouse;
PAS, Periodic Acid Schiff; PCNA, proliferating cell nuclear antigen;
SSA, sulfasalicylic acid; STZ, streptozotocin; TGF-b, transforming
growth factor-beta; TUNEL, terminal deoxynucleotidyl transferase-
mediated nick end labeling.
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